In BRAF-mutated cancers, resistance to BRAF inhibitors frequently involves reactivation of the MAPK pathway through either downstream mutations (e.g., MEK) or BRAF splice variants that promote dimerization, circumventing BRAF inhibition [51]. This evidence concerns the gene BRAF and cancer.